RTx-021 for Stargardt Disease

(AURORA Trial)

This trial tests a new gene therapy called RTx-021 for individuals with Stargardt Disease, an eye condition affecting vision. The researchers aim to evaluate how different doses of this gene therapy work when injected into the eye, enhancing cells' response to light. The trial includes three groups, each receiving a different dose of the treatment. Individuals with a confirmed genetic diagnosis of Stargardt Disease and some remaining retinal cells may qualify. Participants will be monitored for five years to assess the treatment's effects. As a Phase 1/Phase 2 trial, this research focuses on understanding the treatment's function in people and measuring its effectiveness in an initial, smaller group, offering participants a chance to be among the first to benefit from this innovative therapy.

The trial information does not specify if you need to stop taking your current medications. However, if you are using immunosuppressive medications or have certain eye conditions, you may not be eligible to participate.

Research has shown that RTx-021, a gene therapy for Stargardt Disease, is still undergoing safety testing in humans. The treatment involves injecting a gene directly into the eye to help eye cells respond to light. Detailed safety information remains unavailable because the treatment is in the early testing stages. Researchers are closely monitoring how participants handle it. Early trials focus on safety and aim to identify any possible side effects. If participants tolerate RTx-021 well, it would be a positive sign for future studies.¹²³⁴⁵

Researchers are excited about RTx-021 for Stargardt Disease because it uses a novel gene therapy approach to treat vision loss. Unlike current options, which primarily focus on slowing disease progression or managing symptoms, RTx-021 delivers an optogenetic gene directly to the eye through an intravitreal injection. This gene enables retinal cells to produce a light-responsive protein, potentially restoring some degree of vision. The three different dosing arms—low, middle, and high—allow researchers to explore the most effective dose for patients, offering a tailored approach that current treatments do not provide.

Research has shown that RTx-021 might help treat Stargardt Disease by increasing the retina's sensitivity to light. This trial will test various doses of RTx-021, using gene therapy to enable eye cells to produce a light-reactive protein, potentially slowing vision loss or even improving vision. It targets specific retinal cells crucial for sight. Early results appear promising, but further studies on humans are necessary to confirm these benefits. This positions RTx-021 as an exciting new option for individuals with this inherited eye condition.¹³⁴⁵⁶